7 Primary Aldosteronism Symptoms to Watch for

High blood pressure is often blamed on stress, age, weight, salt, or family history. But what if the real reason is a hormone problem that many people never think to check? Aldosteronism, often called primary aldosteronism, happens when the adrenal glands make too much aldosterone. This hormone helps control sodium, potassium, fluid balance, and blood pressure. When levels rise too much, the body may hold on to salt and water while losing potassium, which can push blood pressure higher and create symptoms that feel easy to overlook.

Aldosteronism is more common than many people realize. The Endocrine Society reported in 2025 that an estimated 5% to 14% of people with high blood pressure seen in primary care and up to 30% of people seen in referral centers may have primary aldosteronism. Other research also describes it as the most common endocrine cause of secondary hypertension, with one review noting a prevalence of 14% in newly diagnosed hypertension.

The challenge is that aldosteronism does not always cause obvious symptoms. Some people only know they have high blood pressure that is hard to control. Others may notice muscle weakness, headaches, fatigue, frequent urination, excessive thirst, numbness, or heart palpitations, especially if potassium drops too low. These signs can be mistaken for dehydration, poor sleep, anxiety, or side effects from medication.

This article will walk through 7 aldosteronism symptoms, including the subtle changes that may appear before a clear diagnosis. Keep reading to understand how this hormone condition can affect the body, why it may be missed, and when it may be worth asking a healthcare professional about testing.

What is Primary Aldosteronism?

Primary Aldosteronism is an endocrine disorder defined by the excessive and autonomous production of the hormone aldosterone from the adrenal glands, leading directly to hypertension (high blood pressure) and hypokalemia (low blood potassium).

This condition, also historically known as Conn’s syndrome when caused by a specific type of tumor, represents one of the most common yet frequently underdiagnosed causes of secondary hypertension, where high blood pressure is a symptom of another underlying medical issue. The adrenal glands, small glands located on top of each kidney, are responsible for producing several essential hormones, and aldosterone plays a central role in regulating the body’s electrolyte and water balance.

In a healthy individual, aldosterone release is tightly controlled by the renin-angiotensin-aldosterone system (RAAS), which responds to changes in blood pressure and sodium levels. However, in Primary Aldosteronism, this regulatory feedback loop is broken, and aldosterone is secreted continuously, irrespective of the body’s needs.

This unchecked hormonal activity forces the kidneys to retain sodium and excrete potassium, leading to an expansion of blood volume and a subsequent rise in blood pressure, along with a depletion of the body’s potassium stores.

Why is Recognizing This Condition Important?

Recognizing Primary Aldosteronism is critically important because it is a specific and often treatable cause of hypertension that carries a significantly higher risk of cardiovascular and kidney damage compared to essential (primary) hypertension of the same severity.

Left undiagnosed, the chronic excess of aldosterone exerts direct toxic effects on the heart, blood vessels, and kidneys, independent of its effect on blood pressure. This leads to a substantially elevated risk for severe health events such as stroke, heart attack, atrial fibrillation, and progressive kidney failure.

Studies have consistently shown that patients with Primary Aldosteronism experience these complications at a much higher rate than patients with standard hypertension, even when their blood pressure readings are comparable. Early identification and targeted treatment can mitigate these risks, potentially preventing irreversible organ damage and dramatically improving a patient’s long-term health outlook and quality of life.

More specifically, the importance of recognition can be broken down into several key points. While once considered rare, modern research indicates that Primary Aldosteronism may affect 5-10% of all patients with hypertension and up to 20% of those with treatment-resistant hypertension (high blood pressure that is difficult to control with multiple medications).

This makes it a major public health issue hidden within the larger pandemic of hypertension. Failure to screen for it means a large number of individuals are receiving non-specific treatments that do not address the underlying hormonal driver of their disease.

When Primary Aldosteronism is caused by a unilateral aldosterone-producing adenoma (a benign tumor on one adrenal gland), surgical removal of the affected gland (adrenalectomy) can completely cure the hypertension and hormonal imbalance in a significant number of patients. This offers a rare opportunity to resolve high blood pressure without the need for lifelong medication, a profound benefit that is missed if the condition is not diagnosed.

Targeted therapies, whether surgical or medical (using mineralocorticoid receptor antagonists like spironolactone or eplerenone), specifically block the harmful effects of excess aldosterone. This not only helps control blood pressure more effectively but also directly protects the heart from fibrosis (scarring), reduces the risk of arrhythmias, and preserves kidney function. Standard antihypertensive drugs often fail to provide this same level of targeted organ protection.

The Role of the Hormone Aldosterone

The primary role of the hormone aldosterone is to regulate blood pressure and maintain the body’s balance of crucial electrolytes, specifically sodium and potassium. It is a steroid hormone, classified as a mineralocorticoid, produced in the zona glomerulosa, the outermost section of the adrenal cortex.

Aldosterone executes its functions mainly by acting on the distal tubules and collecting ducts of the kidneys. Its main physiological purpose is to conserve sodium, which in turn helps manage blood volume and, consequently, blood pressure. When the body detects low blood pressure, low sodium levels, or high potassium levels, the renin-angiotensin-aldosterone system (RAAS) is activated, culminating in the adrenal glands releasing aldosterone.

Aldosterone signals the cells in the kidney tubules to increase the number of open sodium channels on their surface. This action promotes the reabsorption of sodium ions from the urine back into the bloodstream. As sodium is reabsorbed, water follows it osmotically, leading to an increase in the volume of fluid in the circulatory system. This expansion of blood volume directly results in an increase in blood pressure.

Simultaneously, aldosterone stimulates the same kidney cells to actively secrete potassium ions from the blood into the urine for excretion. This process is essential for preventing hyperkalemia (dangerously high potassium levels), which can disrupt cardiac rhythm and neuromuscular function. This inverse relationship between sodium retention and potassium excretion is a hallmark of aldosterone’s function.

In Primary Aldosteronism, this finely tuned system is overridden. The adrenal glands produce excessive aldosterone regardless of the body’s renin levels or blood pressure status. This autonomous secretion leads to a state of chronic and inappropriate sodium and water retention, which is the direct cause of the sustained hypertension seen in this condition.

Concurrently, the relentless promotion of potassium excretion leads to the depletion of the body’s potassium stores, resulting in hypokalemia and its associated symptoms like muscle weakness and heart palpitations.

6 Warning Signs and Symptoms of Primary Aldosteronism

Treatment-resistant High Blood Pressure

Treatment-resistant high blood pressure is the most common and pivotal sign of Primary Aldosteronism because the underlying mechanism of the condition, excessive sodium and water retention driven by aldosterone, directly counteracts the effects of many standard antihypertensive medications.

Hypertension is defined as resistant when a patient’s blood pressure remains above their goal (e.g., 130/80 mmHg) despite being on an optimal regimen of three or more blood pressure-lowering drugs from different classes, ideally including a diuretic. In some cases, it may also be defined as blood pressure that is controlled but requires four or more medications. This clinical scenario should immediately raise suspicion for a secondary cause of hypertension, with Primary Aldosteronism being the most prevalent.

The physiological reason for this resistance is straightforward: the root of the problem is hormonal, not vascular or lifestyle-related in the typical sense. Excess aldosterone creates a state of continuous volume expansion. While diuretics work to expel fluid, the aldosterone-driven reabsorption of sodium is so powerful that it can overwhelm their effect. Other medications that work by dilating blood vessels or slowing heart rate do not address the fundamental issue of excess fluid volume, rendering them less effective.

The hypertension is primarily driven by an increased volume of blood in the circulatory system. The constant signal from aldosterone tells the kidneys to “hold onto salt and water,” leading to a persistently expanded plasma volume. This is distinct from many forms of essential hypertension, which may be driven more by vasoconstriction (narrowing of blood vessels).

Patients with Primary Aldosteronism often develop high blood pressure at a younger age (e.g., in their 30s or 40s) than is typical for essential hypertension. The hypertension is also frequently more severe, with higher systolic and diastolic readings that are difficult to manage.

A key biochemical hallmark that accompanies the high aldosterone is a very low or suppressed level of renin, an enzyme that normally initiates the aldosterone production cascade. In a healthy person, high blood pressure would suppress renin. In Primary Aldosteronism, the aldosterone is being produced autonomously, so renin is appropriately suppressed by the high blood pressure, creating a distinctive high-aldosterone/low-renin profile that is a cornerstone of diagnosis.

Low Potassium Levels (Hypokalemia)

Low potassium levels, or hypokalemia, cause a cluster of neuromuscular and cardiac symptoms, including significant muscle weakness or cramps, profound fatigue, and heart palpitations or irregular heartbeats. These symptoms are a direct result of potassium’s critical role in the electrical functioning of nerve and muscle cells throughout the body.

Aldosterone’s primary functions include stimulating the kidneys to excrete potassium into the urine. In Primary Aldosteronism, the chronic overproduction of aldosterone leads to excessive and continuous urinary potassium loss, depleting the body’s total potassium stores and lowering its concentration in the blood.

Although not all patients with Primary Aldosteronism present with overt hypokalemia (some have low-normal potassium levels), when these symptoms are present alongside hypertension, it is a powerful indicator of the condition. The severity of these symptoms often correlates with the degree of potassium depletion.

Potassium is essential for establishing the resting membrane potential of muscle cells, which is necessary for proper contraction and relaxation. When potassium levels are low, this electrical gradient is disrupted, making it harder for muscle cells to fire (depolarize) and then reset (repolarize). This impairment manifests as generalized muscle weakness, a feeling of heaviness in the limbs, and can progress to painful cramps, spasms, or even temporary paralysis in severe cases.

The feeling of pervasive tiredness and lack of energy is common and multifactorial. It stems partly from the generalized muscle weakness but also from the overall metabolic disruption caused by electrolyte imbalance. The body expends significant energy trying to maintain cellular function in a low-potassium environment, leading to a state of exhaustion that is not relieved by rest.

The heart is a muscle that is exquisitely sensitive to potassium levels. Hypokalemia alters the electrical stability of cardiac cells, making them more irritable and prone to abnormal rhythms (arrhythmias). Patients may experience this as palpitations (a feeling of a fluttering, racing, or pounding heart), skipped beats, or more serious arrhythmias like atrial fibrillation. This is one of the most dangerous consequences of untreated hypokalemia.

Frequent Urination and Increased Thirst

Frequent urination (polyuria) and increased thirst (polydipsia) occur in Primary Aldosteronism as a direct consequence of kidney damage induced by chronic low potassium levels. This specific type of renal dysfunction is known as hypokalemic nephropathy. The constant state of hypokalemia, driven by excessive aldosterone, impairs the ability of the kidney tubules to respond to antidiuretic hormone (ADH).

ADH is the hormone responsible for telling the kidneys to reabsorb water and concentrate urine. When the kidney cells are damaged by low potassium, they become resistant to ADH’s signal. As a result, the kidneys lose their ability to concentrate urine effectively and begin to excrete large volumes of dilute urine, regardless of the body’s hydration status.

This obligatory water loss leads to polyuria, where the individual needs to urinate more frequently and produces a larger total volume of urine, which is particularly noticeable at night (nocturia).

This process creates a vicious cycle that explains the accompanying symptom of increased thirst. The excessive loss of water through urination triggers the body’s dehydration-sensing mechanisms. The brain’s thirst center, located in the hypothalamus, detects an increase in the concentration of solutes (like sodium) in the blood.

In response to this signal, the brain generates a powerful sensation of thirst, compelling the individual to drink more fluids. This increased fluid intake, or polydipsia, is the body’s natural attempt to compensate for the massive urinary water losses and prevent severe dehydration.

The patient becomes trapped in a loop of drinking large amounts of water to quench their intense thirst, only to have the kidneys promptly excrete it as dilute urine due to the underlying ADH resistance. Therefore, the combination of hypertension with unexplained frequent urination and thirst should be considered a significant red flag for Primary Aldosteronism, as it points directly to the renal consequences of aldosterone-induced hypokalemia.

Headaches and Blurred Vision

Persistent headaches and blurred vision can be common warning signs, but they are not direct symptoms of high aldosterone itself; rather, they are secondary consequences of the severe and sustained hypertension that the condition causes. Chronically elevated blood pressure exerts immense physical stress on the entire vascular system, and the delicate blood vessels in the brain and eyes are particularly vulnerable to this strain.

When blood pressure remains dangerously high, it can lead to a range of neurological and ophthalmological symptoms that serve as critical indicators of end-organ damage. These symptoms often signal that the hypertension is poorly controlled and has reached a severity level that requires immediate medical attention and investigation into its underlying cause.

While many people with hypertension are asymptomatic, the presence of headaches or vision changes suggests a more advanced or severe stage of the disease, which is characteristic of the hypertension found in Primary Aldosteronism.

While the exact mechanism is debated, severe hypertension is thought to cause headaches by increasing intracranial pressure or by triggering changes in the cerebral blood vessels. These headaches are often described as pulsating, are typically located at the back of thehead (occipital region), and are frequently worse upon waking in the morning. They tend to improve as the day goes on and blood pressure naturally fluctuates. A new onset of such headaches in a person with difficult-to-control blood pressure is a significant clinical clue.

Also, extremely high blood pressure can directly damage the small blood vessels that supply the retina, the light-sensitive tissue at the back of the eye. This condition, known as hypertensive retinopathy, can cause a range of vision problems. The damage can lead to leakage of fluid and blood into the retinal tissue, narrowing of the arteries, and swelling of the optic nerve (papilledema).

Patients may experience blurred vision, double vision, or even sudden vision loss. The presence of hypertensive retinopathy on an eye exam is a definitive sign of severe, systemic vascular damage and strongly suggests the need to search for a secondary cause like Primary Aldosteronism.

Main Causes of Primary Aldosteronism

The two main causes of Primary Aldosteronism are an aldosterone-producing adenoma, which is a benign tumor on a single adrenal gland, and bilateral adrenal hyperplasia, characterized by the non-tumorous overactivity and enlargement of both adrenal glands. These two pathologies account for over 90% of all cases of the condition.

In both scenarios, the result is the same: the adrenal glands produce excessive amounts of aldosterone autonomously, independent of the body’s regulatory renin-angiotensin system. However, the distinction between a unilateral adenoma and bilateral hyperplasia is critically important because it fundamentally dictates the course of treatment.

A unilateral adenoma is often curable with surgery, whereas bilateral hyperplasia is typically managed with lifelong medication. Therefore, a crucial part of the diagnostic process for Primary Aldosteronism involves not only confirming the diagnosis but also determining which of these two underlying causes is present, usually through specialized imaging and sometimes through a procedure called adrenal vein sampling. A much rarer cause is familial hyperaldosteronism, a genetic condition, and in extremely rare instances, an adrenal carcinoma (cancerous tumor) can be the source.

Aldosterone-Producing Adenoma (Conn’s Syndrome)

An aldosterone-producing adenoma is a small, non-cancerous (benign) tumor that develops in the outer layer (cortex) of one of the adrenal glands and independently secretes excessive quantities of aldosterone. This specific cause of Primary Aldosteronism is also historically referred to as Conn’s syndrome, named after Dr. Jerome Conn, who first described the condition in 1955.

These adenomas are “functional” tumors, meaning they actively produce a hormone. The aldosterone secretion from the adenoma is autonomous, meaning it is not controlled by the body’s normal feedback mechanisms, such as the renin-angiotensin system.

As a result, the tumor continuously releases high levels of aldosterone into the bloodstream, leading to the classic clinical picture of sodium retention, potassium loss, suppressed renin, and severe hypertension. Aldosterone-producing adenomas are typically small, often less than 2 centimeters in diameter, and are responsible for approximately 30-40% of all cases of Primary Aldosteronism.

By definition, an adenoma affects only one of the two adrenal glands. This unilateral nature is the most important feature from a treatment perspective. The other adrenal gland is typically healthy and its aldosterone production is suppressed by the high circulating levels from the tumor.

Because the source of the excess hormone is localized to a single, removable tumor, the definitive treatment is a surgical procedure called an adrenalectomy, the removal of the adrenal gland containing the adenoma. In a majority of patients, particularly younger individuals, this surgery can completely cure the hormonal imbalance and resolve the hypertension, eliminating the need for blood pressure medications.

Identifying the adenoma is a critical step. It is typically visualized using imaging techniques like a CT scan or MRI of the adrenal glands. However, because small, non-functional nodules are common in the general population, a procedure called adrenal vein sampling (AVS) is often required to confirm that the nodule seen on the scan is indeed the source of the excess aldosterone before proceeding with surgery.

Bilateral Adrenal Hyperplasia

Bilateral Adrenal Hyperplasia (BAH) is a condition in which both adrenal glands become diffusely enlarged and overactive, leading to the overproduction of aldosterone from both glands simultaneously. Unlike an adenoma, which is a distinct, localized tumor on one gland, hyperplasia involves a more generalized dysfunction affecting the entire aldosterone-producing tissue in both glands.

In this condition, the cells of the zona glomerulosa (the aldosterone-producing layer of the adrenal cortex) increase in number and/or size, resulting in excessive hormone secretion. The exact underlying cause of the most common form, known as idiopathic hyperplasia, is not fully understood, but it is the single most prevalent cause of Primary Aldosteronism, accounting for roughly 60% of cases. Because both glands are involved, the treatment approach is fundamentally different from that for a unilateral adenoma.

The defining characteristic is that both adrenal glands are contributing to the excess aldosterone production. This means there is no single, localized target that can be surgically removed to cure the condition. Attempting to remove both adrenal glands would result in adrenal insufficiency, a serious condition requiring lifelong hormone replacement therapy.

Since surgery is not a viable option, the cornerstone of treatment for bilateral adrenal hyperplasia is medical therapy. Patients are prescribed medications known as mineralocorticoid receptor antagonists (MRAs). The most common drugs in this class are spironolactone and eplerenone. These medications work by directly blocking the aldosterone receptors in the kidneys and other tissues, thereby preventing the harmful effects of the excess hormone. This helps to normalize potassium levels, control blood pressure, and protect the heart and blood vessels from damage.

Treatment with MRAs is typically lifelong. The goal of medical management is to control the symptoms and long-term consequences of aldosterone excess. Regular monitoring of blood pressure, potassium levels, and kidney function is necessary to ensure the medication dosage is optimal and to manage any potential side effects.

Primary Aldosteronism Diagnosis

The Aldosterone-Renin Ratio (ARR) is the principal screening test used to detect Primary Aldosteronism, serving as the first crucial step in the diagnostic pathway. This blood test simultaneously measures the levels of two key hormones: aldosterone, which is produced by the adrenal glands, and renin, an enzyme released by the kidneys.

In a healthy individual, renin and aldosterone levels work in concert; when renin is high, it stimulates aldosterone production, and when renin is low, aldosterone production decreases. The core principle of the ARR test is to identify a breakdown in this relationship.

In Primary Aldosteronism, the adrenal glands autonomously overproduce aldosterone, irrespective of the body’s needs. This high level of aldosterone suppresses the kidneys’ production of renin. Therefore, the hallmark of a positive ARR screen is a high plasma aldosterone concentration coupled with a low or suppressed plasma renin activity, resulting in a significantly elevated ratio.

To ensure the accuracy of the ARR test, specific preparation is often required. The interpretation of the results hinges on several factors, necessitating a standardized approach to testing.

Many blood pressure medications can interfere with aldosterone and renin levels, potentially leading to false-positive or false-negative results. Physicians will often provide a list of medications, such as beta-blockers, ACE inhibitors, and diuretics, that need to be temporarily stopped or switched to less interfering alternatives for several weeks before the test.

Low potassium (hypokalemia), a common symptom of the condition, can suppress aldosterone secretion. It is vital to correct any potassium deficiency before the ARR test is performed to avoid a falsely low aldosterone reading.

Blood should ideally be drawn in the morning after the patient has been upright (sitting, standing, or walking) for at least two hours. This standardized timing helps control for natural hormonal fluctuations that occur throughout the day and with changes in posture.

The Difference Between Primary and Secondary Aldosteronism

The distinction between Primary and Secondary Aldosteronism is fundamental, as it defines the origin of the aldosterone overproduction and dictates the appropriate course of treatment. The core difference lies in the source of the problem: Primary Aldosteronism is caused by an issue within the adrenal glands themselves, leading to autonomous hormone secretion.

In contrast, Secondary Aldosteronism occurs when the adrenal glands are functioning correctly but are being overstimulated by an external factor, typically the renin-angiotensin system. In both conditions, aldosterone levels are high, but the level of renin is the key differentiator.

In Primary Aldosteronism, the high aldosterone levels create negative feedback that suppresses renin, resulting in low renin levels. In Secondary Aldosteronism, the problem originates outside the adrenals, causing the renin-angiotensin-aldosterone system (RAAS) to become overactive, leading to high levels of both renin and aldosterone.

Different Types of Primary Aldosteronism

While Primary Aldosteronism is most commonly caused by an adrenal adenoma or bilateral hyperplasia, there are several other less common and rare subtypes that contribute to the condition’s complexity.

A comprehensive understanding of these variations is essential for accurate diagnosis and specialized management, particularly in cases with a family history or atypical presentation. These rarer forms include genetic predispositions and malignant growths, each with unique characteristics. One of the primary genetic forms is familial hyperaldosteronism (FH), which is inherited.

There are several types of FH, including FH-I, also known as glucocorticoid-remediable aldosteronism (GRA). In GRA, a genetic mutation causes aldosterone production to be regulated by the hormone ACTH, meaning it can be suppressed by steroid medications like dexamethasone. Other genetic forms, such as FH-II, are linked to aldosterone-producing adenomas or hyperplasia running in families but are not remediable with glucocorticoids.

Beyond these inherited forms, malignant tumors represent another rare but critical subtype of Primary Aldosteronism.

Aldosterone-Producing Carcinomas (APCs) are malignant tumors of the adrenal cortex that autonomously secrete aldosterone. While they account for less than 1% of Primary Aldosteronism cases, they are highly aggressive. Patients often present with very high aldosterone levels, severe hypertension, and profound hypokalemia. The diagnosis is typically confirmed after surgical removal and pathological examination of the tumor.

In some instances, hyperplasia (enlargement and overactivity) is confined to just one adrenal gland rather than both. This condition, sometimes called primary adrenal hyperplasia, can behave like an adenoma and may be treatable with surgery.

In extremely rare cases, aldosterone-producing tumors can develop outside the adrenal glands, such as in the ovaries or kidneys. This requires extensive imaging and investigation to locate the source of the excess hormone.

After a Diagnosis

Once a screening test like the Aldosterone-Renin Ratio (ARR) suggests Primary Aldosteronism, a series of subsequent steps are taken to confirm the diagnosis, identify the specific subtype, and establish the most effective treatment plan.

The initial positive screen is not sufficient for a final diagnosis; it must be verified with one or more confirmatory suppression tests. These tests are designed to prove that aldosterone secretion is truly autonomous and is not being appropriately suppressed by the body’s natural mechanisms. Common confirmatory tests include the oral salt loading test, the saline infusion test, or the fludrocortisone suppression test.

During these procedures, the patient is given a high salt load or a synthetic hormone. In a healthy person, this would suppress aldosterone production, but in a patient with Primary Aldosteronism, aldosterone levels remain high.

After confirmation, the next critical step is subtype differentiation: determining whether the excess aldosterone is coming from one adrenal gland (unilateral disease) or both (bilateral disease). This is the single most important factor in deciding the course of treatment.

A high-resolution CT scan of the adrenal glands is typically performed first to look for a visible tumor (adenoma) or signs of enlargement (hyperplasia). However, a CT scan alone is not always conclusive, as small adenomas can be missed, and non-functioning nodules are common.

Considered the gold standard for subtype differentiation, AVS is an invasive radiological procedure. A specialist inserts a catheter into the veins draining each adrenal gland to measure aldosterone levels directly from the source. By comparing the aldosterone levels from each gland, doctors can definitively determine if the overproduction is unilateral or bilateral.

The results of the AVS guide treatment. If the disease is unilateral (e.g., from an aldosterone-producing adenoma), the preferred treatment is surgery (adrenalectomy) to remove the affected gland, which can often cure the hypertension and hypokalemia. If the disease is bilateral (e.g., bilateral adrenal hyperplasia), surgery is not an option. Instead, the condition is managed with lifelong medication, typically mineralocorticoid receptor antagonists like spironolactone or eplerenone, which block the effects of aldosterone.

FAQs

1. Can high aldosterone cause weight gain?

High aldosterone may contribute to weight changes in some people, mainly through fluid retention rather than true fat gain. Aldosterone tells the kidneys to hold on to sodium, and water often follows sodium.

This can increase blood volume, raise blood pressure, and sometimes make a person feel puffy, heavier, or bloated. The Endocrine Society explains that excess aldosterone causes sodium retention, volume expansion, high blood pressure, and, in more severe cases, low potassium.

2. How long can you live with hyperaldosteronism?

Many people can live for years with hyperaldosteronism, especially if it is diagnosed and treated properly. The bigger concern is not the hormone level alone, but the long-term strain it can place on the heart, blood vessels, kidneys, and brain.

Primary aldosteronism is linked with increased cardiovascular complications compared with primary hypertension, and it remains underdiagnosed despite available testing and treatment. With the right care, such as medication or surgery in selected cases, many patients can lower their risks and improve blood pressure control.

3. What does high aldosterone feel like?

High aldosterone may not feel obvious at first. Some people only notice high blood pressure during a routine check. Others may feel headaches, muscle weakness, fatigue, dizziness, increased thirst, frequent urination, numbness, cramps, or heart palpitations, especially if potassium becomes low.

Johns Hopkins notes that excess aldosterone can lead to high blood pressure and, in some people, low potassium levels. Because these symptoms can feel nonspecific, blood testing is often needed to confirm what is happening.

4. How serious is high aldosterone?

High aldosterone can be serious when it is not found or treated. Over time, it may lead to difficult-to-control high blood pressure, low potassium, abnormal heart rhythms, kidney strain, heart disease, stroke risk, and other cardiovascular problems.

Cleveland Clinic notes that untreated high blood pressure raises the risk of complications such as heart attack and stroke, while low potassium can contribute to heart rhythm problems. The good news is that treatment can make a meaningful difference once the cause is identified.

5. What organs does aldosterone affect?

Aldosterone mainly affects the kidneys, but its effects can reach the whole cardiovascular system. The kidneys respond by retaining sodium and releasing potassium, which can increase fluid volume and raise blood pressure.

Because blood pressure affects circulation, high aldosterone can also place extra stress on the heart, blood vessels, and brain over time. Research on aldosterone excess describes possible end-organ damage involving the renal, cardiovascular, and central nervous systems.

6. Does drinking water lower aldosterone?

Drinking water alone usually does not fix high aldosterone. Staying hydrated is important, but primary aldosteronism is a hormone condition that often needs medical evaluation and targeted treatment. Because excess aldosterone makes the kidneys retain salt and water, simply drinking more water may not lower the hormone problem itself.

Healthdirect explains that excess aldosterone encourages the kidneys to keep salt in the body, and retained salt draws water with it, increasing blood volume and blood pressure. People with heart or kidney problems should ask a doctor before making major fluid changes.

Conclusion

Aldosteronism can be easy to miss because it often looks like ordinary high blood pressure. Some people have no clear symptoms at first. Others may notice fatigue, headaches, muscle weakness, frequent urination, excessive thirst, numbness, cramps, or palpitations. These signs may seem small, but they can point to a hormone imbalance that affects blood pressure, potassium, and fluid balance.

The main concern is what happens when high aldosterone stays untreated. It can place long-term pressure on the heart, kidneys, blood vessels, and brain. That is why persistent hypertension, low potassium, or blood pressure that remains hard to control should not be ignored.

Testing can help separate aldosteronism from more common forms of high blood pressure. Once diagnosed, treatment may include medications, lifestyle support, or surgery if one adrenal gland is the main source of excess hormone. The right plan depends on the cause, severity, and overall health.

References

• Adrenal.com – High Aldosterone Symptoms: Recognizing the Signs of Primary Hyperaldosteronism
• Primary Aldosteronism Foundation – Do I Have PA?
• Healthdirect Australia Limited – Primary aldosteronism
• Harvard Health Publishing – Aldosterone overload: An underappreciated contributor to high blood pressure
• UCLA – Hyperaldosteronism
• The Johns Hopkins University – Primary Aldosteronism
• U N D E R S TA N D I N G P R I M A RY ALDOSTERONISM
• Columbia University Irving Medical Center – Guide to Primary Hyperaldosteronism (Conn’s Syndrome)
• PCEDM – PRIMARY ALDOSTERONISM